Jpmorgan Chase & CO Bei Gene, Ltd. Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BGNE
# of Institutions
249Shares Held
45.3MCall Options Held
292KPut Options Held
119K-
Baker Bros. Advisors LP New York, NY10.6MShares$2.05 Billion25.41% of portfolio
-
Capital International Investors Los Angeles, CA6.43MShares$1.25 Billion0.29% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$1.01 Billion26.65% of portfolio
-
Primecap Management CO Pasadena, CA4.97MShares$966 Million0.84% of portfolio
-
Baillie Gifford & CO3.71MShares$720 Million0.64% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $20.1B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...